Institution
British Hospital
Healthcare•Montevideo, Uruguay•
About: British Hospital is a healthcare organization based out in Montevideo, Uruguay. It is known for research contribution in the topics: Population & Lung cancer. The organization has 445 authors who have published 358 publications receiving 7878 citations. The organization is also known as: British Hospital.
Papers published on a yearly basis
Papers
More filters
••
3 citations
••
Mayo Clinic1, Monash University2, University of Oxford3, Memorial Sloan Kettering Cancer Center4, Katholieke Universiteit Leuven5, University of California, San Francisco6, West Virginia University7, Ronald Reagan UCLA Medical Center8, Duke University9, University of Amsterdam10, Hospital Clínico San Carlos11, Utrecht University12, University of Pisa13, Ludwig Maximilian University of Munich14, University of Hamburg15, Yale Cancer Center16, University of Sydney17, University of Crete18, University of Nantes19, UCLA Medical Center20, British Hospital21, Cardiff University22
TL;DR: In this article, the authors assess the potential regional differences in outcomes among patients with metastatic colorectal cancer (mCRC) participating in international randomized clinical trials (RCTs).
Abstract: Background: Benchmarking international cancer survival differences is necessary to evaluate and improve healthcare systems. Our aim was to assess the potential regional differences in outcomes among patients with metastatic colorectal cancer (mCRC) participating in international randomized clinical trials (RCTs). Design: Countries were grouped into 11 regions according to the World Health Organization and the EUROCARE model. Meta-analyses based on individual patient data were used to synthesize data across studies and regions and to conduct comparisons for outcomes in a two-stage random-effects model after adjusting for age, sex, performance status, and time period. We used mCRC patients enrolled in the first-line RCTs from the ARCAD database, which provided enrolling country information. There were 21,509 patients in 27 RCTs included across the 11 regions. Results: Main outcomes were overall survival (OS) and progression-free survival (PFS). Compared with other regions, patients from the United Kingdom (UK) and Ireland were proportionaly over-represented, older, with higher performance status, more frequently male, and more commonly not treated with biological therapies. Cohorts from central Europe and the United States (USA) had significantly longer OS compared with those from UK and Ireland (p = 0.0034 and p < 0.001, respectively), with median difference of 3–4 months. The survival deficits in the UK and Ireland cohorts were, at most, 15% at 1 year. No evidence of a regional disparity was observed for PFS. Among those treated without biological therapies, patients from the UK and Ireland had shorter OS than central Europe patients (p < 0.001). Conclusions: Significant international disparities in the OS of cohorts of mCRC patients enrolled in RCTs were found. Survival of mCRC patients included in RCTs was consistently lower in the UK and Ireland regions than in central Europe, southern Europe, and the USA, potentially attributed to greater overall population representation, delayed diagnosis, and reduced availability of therapies.
3 citations
••
TL;DR: An adverse event reporting method that provides clinically relevant information about treatment toxicity by incorporating two longitudinal adverse event metrics to the traditional maximum grade approach is developed.
Abstract: BackgroundCurrent adverse event reporting practices do not document longitudinal characteristics of adverse effects, and alternative methods are not easily interpretable and have not been employed ...
3 citations
••
3 citations
••
TL;DR: Portuguese Association of Hospital Pharmacists gathered to develop a common positioning on the use of biosimilar monoclonal antibodies for the treatment of autoimmune/inflammatory and oncologic diseases.
Abstract: SummaryWhat is known and Objective
Biopharmaceuticals are an important class of drugs for the treatment of autoimmune/inflammatory and oncologic diseases. With patent expiries, biotechnological manufacturers can now develop biosimilar drugs. Due to timeliness of introducing new and more complex biosimilars, the Portuguese Association of Hospital Pharmacists gathered to develop a common positioning on the use of biosimilar monoclonal antibodies.
Main issues
The European pathway to biosimilar approval was developed to improve affordability and access to biological therapies, but it remains a work in progress because unresolved issues remain. Due to the present reality of biosimilar monoclonal antibodies, hospital pharmacists must play an important role in ensuring the safe, effective and cost-effective use of biosimilars in health systems; and educating healthcare administrators, providers, legislators, policymakers, payors and patients about these products.
What is new and conclusion
The conclusions presented in this work focused on the proposal for optimal biosimilar prescription criteria, the preparation of original biologics and biosimilars in the pharmacy, the management and selection of suppliers, extrapolation issues, the specific role of pharmacovigilance and risk management for the optimal use of biosimilar monoclonal antibodies.
3 citations
Authors
Showing all 445 results
Name | H-index | Papers | Citations |
---|---|---|---|
Maité Garrouste-Orgeas | 62 | 157 | 13270 |
A. de Gramont | 41 | 178 | 11918 |
Ricardo F. Allegri | 33 | 220 | 3577 |
Benoist Chibaudel | 32 | 141 | 4272 |
Emmanuel Marret | 29 | 98 | 4779 |
Federico G. Villamil | 26 | 82 | 3829 |
Oscar E. Martínez | 25 | 174 | 4785 |
Daniel Moya | 21 | 82 | 1236 |
João Guimarães | 19 | 30 | 2206 |
Silvia Quadrelli | 18 | 110 | 1095 |
Jose C. Russi | 17 | 25 | 761 |
Alvaro Campero | 17 | 94 | 1230 |
Hernán Trimarchi | 17 | 79 | 1207 |
Matias Bruzoni | 16 | 46 | 845 |
Hamlet Suarez | 16 | 41 | 914 |